1-12 of 12
Zev A. Wainberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting

Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (7): 1360–1367.
https://doi.org/10.1158/1078-0432.CCR-22-2920
Published: 03 April 2023
View article titled, Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
Open the PDF for Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting in another window
Includes: Supplementary data
Journal Articles

Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy

Zev A. Wainberg, Arun S. Singh, Gottfried E. Konecny, Kelly E. McCann, J. Randolph Hecht, Jonathan Goldman, Bartosz Chmielowski, Richard S. Finn, Neil O'Brien, Erika Von Euw, Megan M. Price, Diego Martinez, Lisa Yonemoto, Meghan Brennan, John A. Glaspy, Dennis J. Slamon
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 40–49.
https://doi.org/10.1158/1078-0432.CCR-22-1553
Published: 04 January 2023
View article titled, Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
Open the PDF for Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Keun-Wook Lee, Eric Van Cutsem, Yung-Jue Bang, Charles S. Fuchs, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee, Hugo R. Castro, Joseph Chao, Zev A. Wainberg, Z. Alexander Cao, Deepti Aurora-Garg, Julie Kobie, Razvan Cristescu, Pooja Bhagia, Sukrut Shah, Josep Tabernero, Kohei Shitara, Lucjan Wyrwicz
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3489–3498.
https://doi.org/10.1158/1078-0432.CCR-22-0121
Published: 15 August 2022
View article titled, Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
Open the PDF for Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study in another window
Includes: Supplementary data
Journal Articles

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

William D. Tap, Arun S. Singh, Stephen Patrick Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Zev A. Wainberg, Igor Puzanov, Gregory M. Cote, Andrew J. Wagner, Fadi Braiteh, Eric Sherman, Henry H. Hsu, Charles Peterfy, Heather L. Gelhorn, Xin Ye, Paul Severson, Brian L. West, Paul S. Lin, Sandra Tong-Starksen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 298–307.
https://doi.org/10.1158/1078-0432.CCR-21-2007
Published: 15 January 2022
View article titled, Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
Open the PDF for Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors

Arun S. Singh, J. Randolph Hecht, Lee Rosen, Zev A. Wainberg, Xiaoyan Wang, Michael Douek, Anahis Hagopian, Rachel Andes, Lauren Sauer, Sandra R. Brackert, Warren Chow, Ronald DeMatteo, Fritz Christian Eilber, John A. Glaspy, Bartosz Chmielowski
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 84–94.
https://doi.org/10.1158/1078-0432.CCR-21-0878
Published: 05 January 2022
View article titled, A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Open the PDF for A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors in another window
Journal Articles

Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10

Zev A. Wainberg, Charles S. Fuchs, Josep Tabernero, Kohei Shitara, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Hyun Cheol Chung, Kensei Yamaguchi, Eniko Varga, Jen-Shi Chen, Daniel Hochhauser, Peter Thuss-Patience, Salah-Eddin Al-Batran, Marcelo Garrido, Uma Kher, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Joseph Chao
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (7): 1923–1931.
https://doi.org/10.1158/1078-0432.CCR-20-2980
Published: 01 April 2021
View article titled, Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10
Open the PDF for Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10 in another window
Journal Articles

Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Zev A. Wainberg, Howard S. Hochster, Edward J. Kim, Ben George, Aparna Kaylan, E. Gabriela Chiorean, David M. Waterhouse, Martin Guiterrez, Aparna Parikh, Rishi Jain, Daniel Ricardo Carrizosa, Hatem H. Soliman, Thomas Lila, David J. Reiss, Daniel W. Pierce, Rafia Bhore, Sibabrata Banerjee, Larry Lyons, Chrystal U. Louis, Teng Jin Ong, Peter J. O'Dwyer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (18): 4814–4822.
https://doi.org/10.1158/1078-0432.CCR-20-0099
Published: 15 September 2020
View article titled, Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Open the PDF for Open-label, Phase I Study of Nivolumab Combined with <em>nab</em>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

Ronan J. Kelly, Jeeyun Lee, Yung-Jue Bang, Khaldoun Almhanna, Mariela Blum-Murphy, Daniel V.T. Catenacci, Hyun Cheol Chung, Zev A. Wainberg, Michael K. Gibson, Keun-Wook Lee, Johanna C. Bendell, Crystal S. Denlinger, Cheng Ean Chee, Takeshi Omori, Rom Leidner, Heinz-Josef Lenz, Yee Chao, Marlon C. Rebelatto, Philip Z. Brohawn, Peng He, Jennifer McDevitt, Siddharth Sheth, Judson M. Englert, Geoffrey Y. Ku
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (4): 846–854.
https://doi.org/10.1158/1078-0432.CCR-19-2443
Published: 14 February 2020
View article titled, Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Open the PDF for Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, III, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5493–5502.
https://doi.org/10.1158/1078-0432.CCR-18-2992
Published: 13 September 2019
View article titled, Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Open the PDF for Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) in another window
Includes: Supplementary data
Journal Articles

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

Manish A. Shah, Alexander Starodub, Sunil Sharma, Jordan Berlin, Manish Patel, Zev A. Wainberg, Jorge Chaves, Michael Gordon, Kevin Windsor, Carrie Baker Brachmann, Xi Huang, Greg Vosganian, Julia D. Maltzman, Victoria Smith, Jeffrey A. Silverman, Heinz-Josef Lenz, Johanna C. Bendell
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (16): 3829–3837.
https://doi.org/10.1158/1078-0432.CCR-17-2469
Published: 14 August 2018
View article titled, Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Open the PDF for Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Philippe L. Bedard, Josep Tabernero, Filip Janku, Zev A. Wainberg, Luis Paz-Ares, Johan Vansteenkiste, Eric Van Cutsem, José Pérez-García, Anastasios Stathis, Carolyn D. Britten, Ngocdiep Le, Kirsten Carter, David Demanse, Denes Csonka, Malte Peters, Angela Zubel, Heidi Nauwelaerts, Cristiana Sessa
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4): 730–738.
https://doi.org/10.1158/1078-0432.CCR-14-1814
Published: 16 February 2015
View article titled, A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Open the PDF for A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

Zev A. Wainberg, Adrian Anghel, Amrita J. Desai, Raul Ayala, Tong Luo, Brent Safran, Marlena S. Fejzo, J. Randolph Hecht, Dennis J. Slamon, Richard S. Finn
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1509–1519.
https://doi.org/10.1158/1078-0432.CCR-09-1112
Published: 28 February 2010
View article titled, Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <em>In vitro</em> and <em>In vivo</em>
Open the PDF for Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab <em>In vitro</em> and <em>In vivo</em> in another window